Incyte Wins EU Approval for Minjuvi After Trial Shows 57% Reduction in Lymphoma Progression Risk

source:

[1] Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (https://finance.yahoo.com/news/incyte-announc ...)

Incyte Wins EU Approval for Minjuvi After Trial Shows 57% Reduction in Lymphoma Progression Risk

Related News

Babcock & Wilcox Secures $40M Refinery Contract

Tesla Profits Plunge 53% as Politics Cost 1.26M Sales

Mizuho Lifts Tesla Target to $530 on Robotaxi Hopes